RemeGen Executive and Leadership Team

Jianmin Fang, the Chief Executive Officer and CSO at RemeGen, directs the company's overall strategic vision and scientific research initiatives. Overseeing the development of innovative drugs for autoimmune diseases and cancers, Fang ensures the robust product pipeline progresses through various research and development stages. This leadership role involves guiding the scientific teams in leveraging advanced technology to create novel therapies like Telitacicept and Disitamab Vedotin. Fang's strategic direction is critical for RemeGen's mission to serve patients globally, focusing on scientific rigor and market impact. The Chief Executive Officer and CSO ensures that scientific discoveries translate into tangible therapeutic solutions, driving the company's growth and commitment to patient well-being. Jianmin Fang's expertise underpins the company's ability to address unmet medical needs in complex disease areas.

Jian Lin, the Executive Director & Chief Executive Officer at RemeGen, spearheads the company's executive leadership and strategic direction. Lin's role encompasses driving the business objectives and ensuring the successful execution of RemeGen's mission to develop innovative biopharmaceutical solutions. This involves overseeing operations that support the advancement of drugs for autoimmune diseases and cancers, including flagship products like Telitacicept and Disitamab Vedotin. The Executive Director & Chief Executive Officer ensures that RemeGen's advanced technology and strong scientific support are effectively utilized to serve patients globally. Jian Lin's leadership focuses on expanding market reach and solidifying the company's position as a leader in therapeutic innovation. This executive function is vital for translating scientific breakthroughs into accessible treatments and achieving sustained growth in the competitive biopharmaceutical landscape.

Shaojing Tong, the Chief Financial Officer at RemeGen, manages the company's financial operations and fiscal strategy. Tong oversees all aspects of financial planning, budgeting, and reporting, ensuring the economic health and sustainability of RemeGen's drug development initiatives. This includes managing investments in the robust product pipeline and supporting the global expansion efforts for innovative therapies like Telitacicept and Disitamab Vedotin. The Chief Financial Officer plays a crucial part in securing funding and optimizing resource allocation to advance research and development for autoimmune diseases and cancers. Shaojing Tong's financial acumen is essential for driving growth and ensuring that RemeGen can effectively serve patients worldwide by maintaining a strong financial foundation. This role is pivotal in translating scientific potential into commercial viability.

Kaisheng Huang, the Chief Operating Officer & Chief Quality Officer at RemeGen, directs the operational execution and ensures the highest standards of quality across all company functions. Huang oversees the manufacturing and supply chain processes critical for producing innovative drugs such as Telitacicept and Disitamab Vedotin, ensuring their availability for patients globally. This leadership role involves implementing rigorous quality control measures throughout the research, development, and production phases for autoimmune diseases and cancers. The Chief Operating Officer & Chief Quality Officer is responsible for optimizing operational efficiency and maintaining compliance with international regulatory standards. Kaisheng Huang's commitment to quality and operational excellence is fundamental to RemeGen's mission of delivering safe and effective therapies. This executive function guarantees the integrity of the company's product pipeline and its global market presence.